Pharmaceutical

AWT-020 by Anwita Biosciences for Sarcomas: Likelihood ...

Dec 26, 2023

AWT-020 is under clinical development by Anwita Biosciences and currently in Pha...

STAT+: The clock is ticking, and Cytokinetics is running out of December

STAT+: The clock is ticking, and Cytokinetics is runnin...

Dec 25, 2023

Want to stay on top of the science and politics driving biotech today? Sign up t...

STAT+: Health data breaches hit an all-time high in 2023

STAT+: Health data breaches hit an all-time high in 2023

Dec 25, 2023

At least 116 million individuals were impacted by large and numerous health data...

STAT+: BioMarin appeases an activist

STAT+: BioMarin appeases an activist

Dec 25, 2023

Want to stay on top of the science and politics driving biotech today? Sign up t...

Devimistat by Cornerstone Pharmaceuticals for Soft Tiss...

Dec 24, 2023

Devimistat is under clinical development by Cornerstone Pharmaceuticals and curr...

(Nanatinostat + valganciclovir) by Viracta Therapeutics...

Dec 24, 2023

(Nanatinostat + valganciclovir) is under clinical development by Viracta Therape...

Enzalutamide by Pfizer for Fallopian Tube Cancer: Likel...

Dec 24, 2023

Enzalutamide is under clinical development by Pfizer and currently in Phase II f...

(Curcumin + doxorubicin) by Immix BioPharma for Colorec...

Dec 24, 2023

(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and cu...

Enzalutamide by Pfizer for Peritoneal Cancer: Likelihoo...

Dec 24, 2023

Enzalutamide is under clinical development by Pfizer and currently in Phase II f...

(Curcumin + doxorubicin) by Immix BioPharma for Metasta...

Dec 24, 2023

(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and cu...

Mecbotamab vedotin by BioAtla for Breast Cancer: Likeli...

Dec 24, 2023

Mecbotamab vedotin is under clinical development by BioAtla and currently in Pha...

(Curcumin + doxorubicin) by Immix BioPharma for Triple-...

Dec 24, 2023

(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and cu...

Lenvatinib mesylate by Eisai for Metastatic Biliary Tra...

Dec 24, 2023

Lenvatinib mesylate is under clinical development by Eisai and currently in Phas...

Opinion: STAT readers on patient advocacy, the utility of diagnostic tests, and more

Opinion: STAT readers on patient advocacy, the utility ...

Dec 23, 2023

“The author owes the FDA an apology”: STAT readers on patient advocacy, the util...

STAT+: FDA alters warning label for Carvykti CAR-T, although link to secondary cancers is unclear

STAT+: FDA alters warning label for Carvykti CAR-T, alt...

Dec 23, 2023

“We do have secondary primary malignancy discussions with patients in the contex...

STAT+: Venture capital is still pouring into drug research despite Medicare price negotiation

STAT+: Venture capital is still pouring into drug resea...

Dec 23, 2023

Drug companies say Medicare drug price negotiation will discourage drug research...